Labeling changes for abacavir.
D019380:Anti-HIV Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000235:genetics; D004348:Drug Labeling; D005820:Genetic Testing / Q000379:methods; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D015235:HLA-B Antigens / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C484830:HLA-B*57:01 antigen